Pathomics Signature for Prognosis and Chemotherapy Benefits in Stage III Colon Cancer,JAMA Surgery

当前位置： X-MOL 学术 › JAMA Surg. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Pathomics Signature for Prognosis and Chemotherapy Benefits in Stage III Colon Cancer
JAMA Surgery ( IF 16.9 ) Pub Date : 2024-02-28 , DOI: 10.1001/jamasurg.2023.8015
Wei Jiang _{1,

2} , Huaiming Wang ₃ , Xiaoyu Dong ₁ , Xian Yu _{1,

4} , Yandong Zhao ₅ , Dexin Chen ₁ , Botao Yan ₁ , Jiaxin Cheng ₁ , Shuangmu Zhuo ₂ , Hui Wang ₃ , Jun Yan _{1,

6}

Affiliation

ImportanceThe current TNM staging system may not provide adequate information for prognostic purposes and to assess the potential benefits of chemotherapy for patients with stage III colon cancer.ObjectiveTo develop and validate a pathomics signature to estimate prognosis and benefit from chemotherapy using hematoxylin-eosin (H-E)–stained slides.Design, Setting, and ParticipantsThis retrospective prognostic study used data from consecutive patients with histologically confirmed stage III colon cancer at 2 medical centers between January 2012 and December 2015. A total of 114 pathomics features were extracted from digital H-E–stained images from Nanfang Hospital of Southern Medical University, Guangzhou, China, and a pathomics signature was constructed using a least absolute shrinkage and selection operator Cox regression model in the training cohort. The associations of the pathomics signature with disease-free survival (DFS) and overall survival (OS) were evaluated. Patients at the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, formed the validation cohort. Data analysis was conducted from September 2022 to March 2023.Main Outcomes and MeasuresThe prognostic accuracy of the pathomics signature as well as its association with chemotherapy response were evaluated.ResultsThis study included 785 patients (mean [SD] age, 62.7 [11.1] years; 437 [55.7%] male). A pathomics signature was constructed based on 4 features. Multivariable analysis revealed that the pathomics signature was an independent factor associated with DFS (hazard ratio [HR], 2.46 [95% CI, 2.89-4.13]; P &lt; .001) and OS (HR, 2.78 [95% CI, 2.34-3.31]; P &lt; .001) in the training cohort. Incorporating the pathomics signature into pathomics nomograms resulted in better performance for the estimation of prognosis than the traditional model in a concordance index comparison in the training cohort (DFS: HR, 0.88 [95% CI, 0.86-0.89] vs HR, 0.73 [95% CI, 0.71-0.75]; P &lt; .001; OS: HR, 0.85 [95% CI, 0.84-0.86] vs HR, 0.74 [95% CI, 0.72-0.76]; P &lt; .001) and validation cohort (DFS: HR, 0.83 [95% CI, 0.82-0.85] vs HR, 0.70 [95% CI, 0.67-0.72]; P &lt; .001; OS: HR, 0.80 [95% CI, 0.78-0.82] vs HR, 0.69 [0.67-0.72]; P &lt; .001). Further analysis revealed that patients with a low pathomics signature were more likely to benefit from chemotherapy (eg, combined cohort: DFS: HR, 0.44 [95% CI, 0.28-0.69]; P = .001; OS: HR, 0.43 [95% CI, 0.29-0.64]; P &lt; .001).Conclusions and RelevanceThese findings suggest that a pathomics signature could help identify patients most likely to benefit from chemotherapy in stage III colon cancer.

更新日期：2024-02-28

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>